3Oldham RK.Biologicals and biological response modifiers: fourth modality of cancer treatment. Cancer Treat Rep,1984;68(1):221.
4Den Otter W, Maas RA, Koten JW, et al. Effective immunotherapy with local low doses of interleukin-2.In Vivo,1991;5(6):561.
5Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science,1986;233(4770):1318.
6Schofield L, McConville MJ, Hansen D, et al. CD1d-restricted immunoglobulin G formation to GPI-anchored antigens mediated by NKT cells. Science,1999;283(5399):225.
7Lanier LL. Follow the leader: NK cell receptors for classical and nonclassical MHC class I. Cell,1998;92(6):705.
8Farace F, Angevin E, Dietrich PY, et al. Low-dose IL-2 treatment: activation of discrete T-and NK-cell sub-populations in vivo. Int J Cancer,1995;62(5):523.
9Cao Zeyi, Zhang dan, Pen Zilan, et al. Chemotherapy for lymphatic metastatic gynecologic cancer via pelvic retroperitoneal cannulation.Gynecol Oncol,1996;63(9):358.
10Savage P, So A, Spooner R A, Epenetos A A. A recombinant single chain antibody interleukin-2 fusion protein. Br J Cancer, 1993, 67:304 - 310
